AMILI raises US$10.5M Series A led by Microsoft co-founder’s VC fund to expand in SEA

Singapore-based precision gut microbiome company AMILI has secured US$10.5 million in Series A financing.

(The gut microbiome consists of trillions of bacteria, viruses, and fungi that live in the digestive tract. It plays a key role in almost every aspect of human health.)

Vulcan Capital, the investment arm of the late Microsoft Corp Co-Founder Paul Allen that invests in category-leading technology, internet and life sciences companies, led this round.

Pruksa Group, TVM Capital Healthcare, Emtek Group, Capital Code, Pureland Group, Blue7, GK Goh, and SEEDS Capital also participated.

AMILI will use the capital to accelerate its expansion in Southeast and Greater Asia. The funds will also be used to accelerate microbiome research partnerships and discovery and develop AMILI Prime.

Also Read: How biotech is changing the global agriculture game for investors

AMILI offers three products: (i) a multi-ethnic Asia microbiome database, (ii) a microbiome bank with samples stored for metagenomic and metabolomic analysis, and (iii) AMILI PRIME, a set of proprietary analytical tools, informatics pipelines and discovery engines.

These core assets are used to power the firm’s four commercial engines:

Diagnostics and therapeutics: It works closely with academic institutions and biotech companies to identify novel biomarkers, elucidate mechanistic pathways and formulate products to modify the gut microbiome and treat disease.

Faecal microbiota transplants: Collection, analysis and processing of FMT preparations used by patients, hospitals and research institutes across the region.

Personalised wellness: It is offered under the direct-to-consumer brand BIO & ME, which includes gut health testing services and personalised supplements developed through AMILI PRIME based on multi-ethnic Asia data.

Food for Health: Partnerships with food manufacturers and retailers to assist them in product validation, measurement and development. AMILI provides them with insights into the impact of various ingredients, recipes and foods on the human microbiome, particularly concerning the consumer in Asia.

Since its inception, the startup claims to have established more than 20 research studies across a wide range of health indications, with a total grant value exceeding S$60 million.

The firm plans to expand its BIO & ME product into the rest of Southeast Asia and Hong Kong in 2022.

—

The post AMILI raises US$10.5M Series A led by Microsoft co-founder’s VC fund to expand in SEA appeared first on e27.